Petlife Pharmaceuticals, Inc. (PTLF) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
Beta 3.91: the stock has moved about 291% more than the S&P 500.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 16, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerPetlife Pharmaceuticals, Inc. (PTLF) trades at $0.0001. Petlife Pharmaceuticals, Inc. focuses on researching, developing, and selling drugs and nutraceuticals for pet cancer and autoimmune diseases. Sector: Healthcare.
Price as of · Last analyzed: Mar 16, 2026Analyst Coverage for PTLF: PTLF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
Petlife Pharmaceuticals, Inc. (PTLF) Healthcare & Pipeline Overview
Petlife Pharmaceuticals, Inc. is a development-stage pharmaceutical company targeting the pet healthcare market with drugs and nutraceuticals for cancer and autoimmune diseases. Its lead product, Vitalzul, aims to inhibit blood vessel formation in tumors, positioning the company within the niche market of specialized pet therapeutics and edible treatments.
What Is the Investment Thesis for PTLF?
Petlife Pharmaceuticals, Inc. presents a high-risk, high-reward investment profile due to its focus on a niche market within the pet healthcare industry. The company's primary value driver is the successful development and commercialization of Vitalzul, its lead drug candidate for treating tumors in pets. Key catalysts include the progression of Vitalzul through clinical trials and regulatory approval processes. However, the company faces significant risks, including limited financial resources, reliance on a single product, and competition from established pharmaceutical companies. With a market capitalization of $0.00B and a negative P/E ratio, the company's financial stability is uncertain. The high beta of 3.91 indicates significant volatility. Investors should carefully consider these factors before investing.
Based on FMP financials and quantitative analysis
PTLF Key Highlights
Petlife Pharmaceuticals focuses on drugs and nutraceuticals for pet cancer and autoimmune diseases.
- Their main product, Vitalzul, targets blood vessel formation in solid tumors.
- The company is developing Vitalzul in oral, intravenous, and injectable forms.
- Petlife Pharmaceuticals also develops edible dog and cat treats.
- The company has a market capitalization of $0.00B and a negative P/E ratio.
Who Are PTLF's Competitors?
PTLF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| AKAN Akanda Corp. | $1.98 | -10.41% | — | |
| SNOA Sonoma Pharmaceuticals, Inc. | $1.24 | -0.80% | $5.94M | — |
| BFRI Biofrontera Inc. | $1.01 | -2.40% | $13.0M | — |
| COSM COSM | $0.38 | -1.58% | $20.7M | — |
| QNTM Quantum BioPharma Ltd. | $3.44 | +0.44% | $22.0M | — |
| AYTU Aytu BioPharma, Inc. | $2.07 | -0.96% | $22.2M | — |
| TXMD TherapeuticsMD, Inc. | $2.05 | +0.99% | $23.7M | — |
| CPHI CPHI | $0.66 | +0.61% | $26.6M | — |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are PTLF's Key Strengths?
Proprietary drug candidate (Vitalzul) targeting a specific mechanism of action.
- Focus on the growing pet healthcare market.
- Development of multiple formulations (oral, IV, injectable).
- Potential for edible treat products to supplement revenue.
What Are PTLF's Weaknesses?
Limited financial resources and small market capitalization.
- Reliance on a single product (Vitalzul).
- Limited operating history and commercialization experience.
- High beta indicating significant stock volatility.
What Are the Key Risks for PTLF?
Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Failure to obtain regulatory approval for Vitalzul.
- Competition from established veterinary pharmaceutical companies.
- Limited financial resources and high cash burn rate.
- Reliance on a single product (Vitalzul).
- Adverse clinical trial results.
What Are PTLF's Competitive Advantages?
- Proprietary drug formulations, particularly Vitalzul.
- Focus on a niche market within the pet healthcare industry.
- Potential for strong relationships with veterinary clinics.
- Development of companion diagnostics to enhance treatment effectiveness.
What Does PTLF Do?
Petlife Pharmaceuticals, Inc., based in Los Angeles, California, is a specialty pharmaceutical company focused on the research, development, sale, and support of drugs and nutraceuticals for pet cancer and autoimmune-related diseases, such as arthritis. The company's core product is Vitalzul, a compound designed to inhibit blood vessel formation in solid tumors, thereby cutting off their nutrient supply and hindering growth. Vitalzul is currently being developed in several forms, including a prescription-strength oral pharmaceutical, a concentrated intravenous version, and an injectable formulation for direct tumor administration. In addition to its pharmaceutical endeavors, Petlife Pharmaceuticals also develops edible dog and cat treats, potentially offering a dual approach to pet health by combining therapeutic benefits with palatable formats. Founded with the vision of addressing unmet medical needs in the pet healthcare sector, the company aims to provide innovative solutions for diseases that significantly impact the quality of life for pets. As of 2026, Petlife Pharmaceuticals operates with a small team, emphasizing its stage as a development-focused entity with aspirations for future commercial expansion.
What Products and Services Does PTLF Offer?
- Researches and develops drugs for pet cancer and autoimmune diseases.
- Focuses on creating nutraceuticals for pets.
- Develops Vitalzul, a drug that inhibits blood vessel formation in solid tumors.
- Creates oral, intravenous, and injectable versions of Vitalzul.
- Manufactures edible dog and cat treats.
- Sells and supports its products in the United States.
How Does PTLF Make Money?
- Develops and patents pharmaceutical products for pets.
- Generates revenue through the sale of prescription drugs and nutraceuticals to veterinary clinics and pet owners.
- Explores partnerships and licensing agreements to expand market reach.
- Develops and sells edible pet treats as a complementary revenue stream.
What Industry Does PTLF Operate In?
The pet healthcare industry is experiencing significant growth, driven by increasing pet ownership and a greater willingness among owners to spend on their pets' health and well-being. This includes specialized treatments for conditions like cancer and autoimmune diseases. Petlife Pharmaceuticals operates within this expanding market, focusing on a niche segment with its Vitalzul product. The competitive landscape includes established veterinary pharmaceutical companies and other emerging players developing innovative therapies for pets. The overall market is characterized by increasing demand for advanced veterinary care and specialized pet health products.
Who Are PTLF's Key Customers?
- Veterinary clinics and hospitals that treat pets.
- Pet owners seeking advanced treatment options for their pets.
- Distributors of veterinary pharmaceuticals and pet products.
- Online retailers specializing in pet health products.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Company Profile
Petlife Pharmaceuticals, Inc. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Los Angeles, US. The company is led by CEO Sebastian Serrell-Watts. PTLF has traded publicly since 2008.
Financial Health
Petlife Pharmaceuticals, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
PTLF Financials
PTLF Latest News
No recent news available for PTLF.
PTLF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for PTLF.
Price Targets
Wall Street price target analysis for PTLF.
PTLF MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for PTLF; grades run from A+ (80-100) to F (below 30).
Leadership: Sebastian Serrell-Watts
CEO
Sebastian Serrell-Watts serves as the CEO of Petlife Pharmaceuticals, Inc. Additional research would be required to provide a comprehensive overview of his career history, educational qualifications, and prior roles before joining Petlife Pharmaceuticals.
Track Record: Due to the limited information available, it is not possible to provide a detailed track record of Sebastian Serrell-Watts' achievements and strategic decisions at Petlife Pharmaceuticals. The company's milestones and performance under his leadership require further investigation and data collection.
PTLF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Petlife Pharmaceuticals may not meet the minimum financial standards or disclosure requirements of higher tiers like OTCQX or OTCQB. Companies in this tier often have limited regulatory oversight and may not provide regular financial reporting, increasing the risk for investors compared to companies listed on major exchanges like NYSE or NASDAQ. This tier is typically associated with speculative investments and requires careful due diligence.
- OTC Tier: OTC Other
- Limited financial disclosure and regulatory oversight.
- Potential for price manipulation and fraud.
- Higher bid-ask spreads and lower trading volume.
- Greater risk of delisting or trading suspension.
- Limited access to company information and management.
- Verify the company's legal registration and business operations.
- Review available financial statements and disclosures.
- Assess the company's management team and their experience.
- Understand the company's business model and competitive landscape.
- Evaluate the company's intellectual property and patent portfolio.
- Monitor trading volume and price volatility.
- Consult with a financial advisor before investing.
- Existence of a functional website and contact information.
- Press releases and public announcements about company activities.
- Patent filings or intellectual property registrations.
- Partnerships or collaborations with reputable organizations.
- Positive media coverage or industry recognition.
PTLF Healthcare Stock FAQ
What do analysts say about PTLF stock?
As of 2026-03-16, there is no available analyst coverage or consensus on Petlife Pharmaceuticals, Inc. (PTLF) due to its small market capitalization and OTC listing. Key valuation metrics such as price targets and earnings estimates are not available.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Limited information available on the company's financials and operations.
- OTC market carries higher risks compared to major exchanges.